Metabolomic Profiling in Individuals with a Failing Kidney Allograft

PLoS One. 2017 Jan 4;12(1):e0169077. doi: 10.1371/journal.pone.0169077. eCollection 2017.

Abstract

Background: Alteration of certain metabolites may play a role in the pathophysiology of renal allograft disease.

Methods: To explore metabolomic abnormalities in individuals with a failing kidney allograft, we analyzed by liquid chromatography-mass spectrometry (LC-MS/MS; for ex vivo profiling of serum and urine) and two dimensional correlated spectroscopy (2D COSY; for in vivo study of the kidney graft) 40 subjects with varying degrees of chronic allograft dysfunction stratified by tertiles of glomerular filtration rate (GFR; T1, T2, T3). Ten healthy non-allograft individuals were chosen as controls.

Results: LC-MS/MS analysis revealed a dose-response association between GFR and serum concentration of tryptophan, glutamine, dimethylarginine isomers (asymmetric [A]DMA and symmetric [S]DMA) and short-chain acylcarnitines (C4 and C12), (test for trend: T1-T3 = p<0.05; p = 0.01; p<0.001; p = 0.01; p = 0.01; p<0.05, respectively). The same association was found between GFR and urinary levels of histidine, DOPA, dopamine, carnosine, SDMA and ADMA (test for trend: T1-T3 = p<0.05; p<0.01; p = 0.001; p<0.05; p = 0.001; p<0.001; p<0.01, respectively). In vivo 2D COSY of the kidney allograft revealed significant reduction in the parenchymal content of choline, creatine, taurine and threonine (all: p<0.05) in individuals with lower GFR levels.

Conclusions: We report an association between renal function and altered metabolomic profile in renal transplant individuals with different degrees of kidney graft function.

MeSH terms

  • Adult
  • Chromatography, Liquid
  • Creatinine / urine
  • Female
  • Glomerular Filtration Rate / physiology
  • Humans
  • Kidney Transplantation*
  • Male
  • Metabolomics / methods*
  • Middle Aged
  • Multivariate Analysis
  • Tandem Mass Spectrometry

Substances

  • Creatinine

Grants and funding

This work was supported by a AST Genentech/Novartis Clinical Science Fellowship grant to RB and an Italian Society of Diabetes (AMD-SID) Pasquale di Coste Award to RB. RB was supported by a JDRF Post-Doctoral Research Fellowship grant. MAN received a JDRF Career Development Award (5-CDA-2015-89-A-B). PF was supported by an American Heart Association (AHA) Grant-In-Aid and the Italian Ministry of Health (grant RF-2010-2303119). PF also received support from the EFSD/Sanofi European Research Programme. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.